Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Metlife ( (MET) ) has shared an update.
On June 17, 2025, MetLife, Inc. entered into a Note Purchase Agreement for the private placement of ¥87,840,000,000 in yen-denominated senior notes with varying interest rates and maturities. The proceeds from the sale are intended for refinancing existing debt and general corporate purposes, reflecting MetLife’s strategic financial management and positioning within the industry.
The most recent analyst rating on (MET) stock is a Buy with a $85.00 price target. To see the full list of analyst forecasts on Metlife stock, see the MET Stock Forecast page.
Spark’s Take on MET Stock
According to Spark, TipRanks’ AI Analyst, MET is a Outperform.
MetLife’s strong financial performance, strategic risk management, and favorable corporate events drive a positive overall outlook. While technical indicators suggest caution, the company’s robust earnings growth and strategic initiatives enhance its long-term prospects.
To see Spark’s full report on MET stock, click here.
More about Metlife
MetLife, Inc. is a leading global provider of insurance, annuities, and employee benefit programs, serving 90 million customers in over 60 countries. The company is known for its strong market presence in the life insurance sector and offers a wide range of financial services.
Average Trading Volume: 3,470,992
Technical Sentiment Signal: Buy
Current Market Cap: $52.63B
For a thorough assessment of MET stock, go to TipRanks’ Stock Analysis page.